BioNTech
NEWS
If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.
Some fear potential side effects, and more just aren’t sure about the quality and risks associated with a vaccine developed in an unprecedented nine months.
The U.S. Food and Drug Administration posted analyses of the Pfizer-BioNTech COVID-19 vaccine in children ages 5 to 11 years old ahead of Tuesday’s vaccines advisory committee meeting.
The U.S. FDA has a busy period at the end of October heading into the first week of November.
It was yet another busy week for clinical trial news. Here’s a look.
Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.
The CDC supported the FDA’s approval of mixing and matching vaccines, where eligible populations can take a booster shot from another brand different from their initial series.
The Pfizer-BioNTech mRNA COVID-19 vaccine is reportedly the top vaccine used globally. Here’s a look at today’s highlights.
The U.S. FDA approved the use of Moderna’s and Janssen’s COVID-19 vaccines as a booster dose after their primary versions are completed.
JOBS
IN THE PRESS